Trial results showed vaccine efficacy of 90% was given as a half dose, followed by a full dose at least one month apart.
Oxford University said that interim analysis from its phase three vaccine trial shows that the 70% effectiveness comes from combining two doses.
One was 90% effective, the other 62%
In a statement, Professor Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford Vaccine Trial, said:
“These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.
“Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.”
